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ABSTRACT 
 
In the present study crystal structure of 3-[Bis-(2-hydroxy-4,4-dimethyl-6-oxo-cyclohex-1-enyl)-methyl]benzonitrile 
was determined using single crystal X-ray diffraction. Further the structural features was extrapolated to molecular 
docking studies with focal adhesion kinase (FAK) domain using Autodock to study its anticancerous property. The 
compound exhibited considerable bacterial inhibition of lower to moderate concentrations. We conclude that these 
derivatives can be used in medicine and have enormous potential as pharmaceutical agents due to their biological 
activities. The above titled receptor gain functional and structural insights into their mechanism of inhibition and 
explore its potential as an anticancer agent. 
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INTRODUCTION 
 
Cyclohexane is a non planar molecule and the shape of which is vaguely resembles a chair. The conformation of 
cyclohexane molecule is constantly changing with the atom on the left, which is currently pointing down, flipping 
up and the one on the right flipping down. During the process, another (slightly less stable) form of cyclohexane is 
formed known as the "boat" form [1,2]. In this arrangement, both of these atoms are either pointing up or down at 
the same time. It is a cyclic alkane that melts at 6°C and boils at 81°C. It is nearly insoluble in water. Cyclohexane is 
found naturally to some extent in petroleum, but is prepared commercially by catalytic hydrogenation of benzene. It 
is widely used as a solvent and in making certain compounds used in the preparation of nylon. The biological 
importance of cyclohexane has resulted in the synthesis of substituted derivatives, which show potent 
pharmaceutical activities like antimicrobial, antidiabetic, anticancer antipsychotic, anesthetic, expectorant activities 
[3-5]. Focal adhesion kinase is a cytoplasmic non-receptor protein tyrosine kinase, which was isolated for the first 
time by co-immunoprecipitation of tyrosine-phosphorylated proteins from cells transformed with Rous sarcoma 
virus v-Src. Non-receptor protein-tyrosine kinase (PTK2/FAK1) that plays an essential role in regulating cell 
migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal 
adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. It is required for early 
embryonic and placenta development. It also required for embryonic angiogenesis, normal cardiomyocyte migration 
and proliferation, and normal heart development. It regulates axon growth and neuronal cell migration, axon 
branching and synapse formation; required for normal development of the nervous system. It Plays a role in 
osteogenesis and differentiation of osteoblasts. It helps in function of integrin signal transduction, but also in 
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signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin 
receptors and LDL receptors. The aberrant PTK2/FAK1 expression may play a role in cancer cell proliferation, 
migration and invasion, in tumor formation and metastasis. PTK2/FAK1 overexpression is seen in many types of 
cancer[6,7]. 
 
MATERIALS AND METHODS 
 
For crystallographic analysis data collection and cell refinement was done using CAD-4, Data reduction using 
MOLEN, Structure solution and refinement using SHELX97[8], Molecular graphics using ORTEP [9] & 
PLATON[10], Material for publication using SHELX97 and for protein-ligand interaction using Autodock software. 
File format conversion of the coordinates using openbabel [11]. 
 
Crystallization of KCH1 
The crystals of the compound 3-[Bis-(2-hydroxy-4,4-dimethyl-6-oxo-cyclohex-1-enyl)-methyl]benzonitrile (KCH1) 
was grown by slow evaporation technique using ethanol as solvent. The X-ray intensity data of the crystals were 
collected on a Bruker smart CCD diffractometer on graphite monochromatic Mokα radiation.  
 
Protein-Ligand Interaction 
The docking analysis of KCH1 with Crystal Structure of Focal Adhesion Kinase Domain Complexed with 7H-
Pyrrolo [2,3-d] pyrimidine Derivative (PDB:2ETM) was carried using Autodock 4.2 [12]. The reference ligand 7PY 
(7-Pyridin-2-Yl-N-(3,4,5-Trimethoxyphenyl)-7h-Pyrrolo[2,3-D]pyrimidin-2-Amine) was selected for binding site 
analysis and respective amino acids are considered for gridbox construction. The docking site for KCH1 on 2ETM 
was defined at the position of the co-crystallized ligand 7PY by using PyRX 0.8 interface with grid box size of 56 x 
55 x 56, spacing of 0.375, grid centre -1.220, 11.661 and 6.401 and assigning all possible “Degrees of Freedom” to 
all ligands. From the estimated free energy of ligand binding (∆G), the inhibition constant (Ki) for each ligand was 
calculated Docking of the protein ligand complex was mainly targeted to the predicted active site. The interaction 
was carried out to find the favorable binding geometries of the ligand with the protein. The selected residues of the 
receptor were defined to be part of the binding site. The molecules binding to a receptor, ideally must inhibit its 
function, and thus act as a drug. The collection of bis cyclohexyl diols derivatives and receptor complexes were 
identified via docking. The scoring functions with their parameters were read from the score obtained. The entire 
series of ligands in the data set was docked into the active site of FAK protein, using the same protocol. The docking 
poses were saved for the ligand and were ranked according to their score function. The pose possessing the highest 
dock score was selected for further analysis. PyMOL and Ligplot+ were used for docking conformation 
representation [13,14]. Only the best pose (the one with the lowest binding energy) was considered as a potential 
ligand. 
 
RESULTS AND DISCUSSION 
 
The molecule, C24H27NO4 crystallizes in monoclinic space group P21/c with unit cell dimensions, a=11.8048(13)Å, 
b=11.46769(13)Å, c=16.52539(19)Å and Z=4. The ORTEP diagram of the ligand showing 50% probability 
displacement ellipsoids is shown in figure 1. The crystal data of the compound are shown in table1.The bond lengths 
and bond angles are generally within the normal range. The cyclohexenone ring A (C6/C5/C4/C1/C2/C3) and the 
benzene ring B (C22-C27) are not planar. The cyclohexene ring constitutes a part of the tetra benzonitrile fused ring. 
The bond length O8-C13 is 1.26Å and C1-C2 is 1.38Å for the both cyclohexene ring. A part of the benzonitrile 
fused ring system has a flattened half-chair conformation that approximates an envelope conformation (in which the 
methylene C atom bearing the dimethyl substituent represents the flap) as five of the six atoms lie on a plane[15,16]. 
The mean plane of the cyclohexene ring with the hydroxyl substituent is approximately perpendicular to the mean 
plane of the tetra benzonitrile system. Adjacent molecules are linked by an O-H...O hydrogen bond to form a chain 
running along the b-axis of the monoclinic unit cell. The dihedral angle between the benzonitrile ring and 
cyclohexene ring is 70.8°. Relatively strong intramolecular O-H…O hydrogen bonds are observed. In the crystal, 
molecules are linked by C-H…O hydrogen bonds, forming a chain along the c-axis direction. There is an 
intramolecular hydroxy–ketone O-H…O interaction between the two substituted cyclohexane rings as well as a 
short intramolecular phenol–methoxy O-H…O interaction.The packing diagram C-H…O and O-H…O interactions 
is shown in Fig 2 [17]. 
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Fig1: Ortep diagram of 3-[Bis-(2-hydroxy-4,4-dimethyl-6-oxo-cyclohex-1-enyl)-methyl]benzonitrile 
 
Table1: Crystal data 
 
Identification and  CCDC code KCH1                     1016197 
Empirical formula C24 H27 N O4 
Formula weight 393.46 
Temperature 298(2) K 
Wavelength 1.54  Å 
Crystal system monoclinic 
Space group P21/c 
Unit cell dimensions a=11.8048(13) Å    α=900 
b=11.46769(13) Å  β=108.460 
c=16.52539(19) Å   γ=900 
Volume 2121.9(4) A3 
Z 4 
Calculated density 1.232Mg/m3 
Absorption coefficient 0.672mm^-1 
F (000) 840 
Crystal size 0.4 x0.35x0.2mm 
Theta ranges for data collection 9.556 to 58.708 deg 
Limiting indices -13 ≤ h ≤ 13, -5 ≤ k ≤ 13, -19 ≤ l ≤ 18 
Reflections collected / unique 13517/3489 [R(int)=0.0290] 
Completeness to theta 98.2% 
Absorption correction None 
Refinement method Full matrix least  squares on F^2 
Data / restraints / parameters 3489/0/274 
Goodness-of-fit on F^2 1.035 
Final R indices [I>2sigma(I)] R1=0.0379, wR2=0.0972 
R indices (all data) R1=0.0421 wR2=0.1005 
Absolute structure parameter 0.8(2) 
Extinction coefficient 0.0018 (16) 
Largest diff. peak and hole 0.14 and -0.13 e A^-3 
 
The in silico interaction of 7-pyridin-2-yl-n-(3,4,5-trimethoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine (7PY) to 
2ETM showed the least binding energy of -6.42kcal/mol. From the PDBsum, it is observed that 7PY forms two 
hydrogen bonds with CYS502 with bond length of 3.11Å and 2.91Å (Image not showed). The conformation with 
least binding energy and most stability based on cluster analysis was taken for docking analysis. In the Autodock 
predicted interaction, it shows the interaction as hydrophobic and due to this the inhibition constant value increased 
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from 0.212µM to 19.68 µM. Since Autodock calculates the inhibition constant from the binding energy and both 
7PY and KCH1 has the same energy, we observe nearly the same IC50 values and may act by competitive 
inhibition. The interacting residues in both 7PY and KCH1 are almost conserved. KCH1 shows a hydrophobic 
interaction as showed in Figure 3 and Figure 4. The docking interaction details are represented in Table2. Since the 
synthesized chemical compound showed good fit with the protein, the bioactive compound may be used as a potent 
inhibitor to block the action of FAK protein.  
 
 
Fig.2 Packing diagram showing C – H … O and O --H…O interactions indicated as dashed lines. H atoms not involved in hydrogen 
bonding have been  omitted 
 
Table2: Docking interaction details of KCH1 and 7PY against FAK protein 
 
Compound 
Binding 
energy 
Kcal/mol 
Intermol 
energy 
Inhibition 
constant 
µM 
Interacting residues of amino acids 
7PY -6.42 -7.91 19.68 ILE428, GLY429, VAL436, ALA452, GLU500, LEU501, CYS502, GLY505, LEU553 
KCH1 -6.42 -7.91 19.76 ILE428, GLY429, VAL436, ALA452, GLU500, LEU501, CYS502, GLY505 
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Fig3: Interaction of KCH1 with 2ETM 
 
 
Fig4: Interaction of KCH1 in the active site of FAK protein 
 
CONCLUSION 
 
In the present study, topological analysis of 3-[Bis-(2-hydroxy-4,4-dimethyl-6-oxo-cyclohex-1-enyl)-
methyl]benzonitrile is performed using crystallographic method. The results were extrapolated to molecular docking 
analysis to investigate the structure–activity relationship between the inhibitory features of KCH1 ligand. From the 
AutoDock result, it can be concluded that the bioactive compound KCH1 can be used as a potent inhibitor to block 
the action of FAK protein when it is over expressed. Further, the bioactive compound will be analyzed by molecular 
dynamics studies and then in vivo studies for detailed investigations. Further co-crystallization of protein-ligand 
complex and animal trials followed by biopharmaceutical scale up feasibilities could be encouraged. 
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